nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01752257,EF5 in Melanoma Patients,0.002208514532613731,0.0010035394174090731
NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",0.0007247257810012852,0.0009665135235314094
NCT01748747,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,0.0010496503047770637,0.0013234257661917774
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,0.0010257742107890172,0.0007279652387658751
NCT01703507,Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma,0.0008978830405856041,0.0009604652128935677
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,0.0022085145326137365,0.0024193828677836374
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.0009654803475985324,0.000765155377189927
NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer",0.0010579739743551747,0.0012358690376874644
NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,0.001061247814026683,0.001121781204583685
NCT01744171,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,0.0012944929786352648,0.0014638607802425988
NCT01744860,Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples,0.0007713459197660718,0.0009572919471594094
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,0.0009543029667457974,0.0009674796727899391
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002),0.0010253544013597978,0.0008847669683280105
NCT01776905,In Vivo Real-time Detection of Circulating Melanoma Cells,0.0010583604838428132,0.0007539187236869168
NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,0.0010938416202388092,0.0010773984297965111
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,0.0011259253479219936,0.0010068802811936482
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",0.0011606443539365623,0.0011412053915456064
NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,0.0011345821818882491,0.001301580588229465
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,0.0009158855575988815,0.000983285838077076
NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,0.001156289588873524,0.0011748689820079315
NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),0.0012188761919835584,0.001212993124007714
NCT01721603,A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,0.0008705240811429085,0.00091637218701465
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011292831598845284,0.0012265623230282726
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,0.001492479585372951,0.0009013947446452374
NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,0.0010497014346299,0.0010510342291272076
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,0.0009261119325586555,0.0010444965465853987
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0008572417599263474,0.000879685039133529
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,0.0008842576948050603,0.000997861472940032
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,0.0011302256495496136,0.0009284634369550375
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,0.001436043418714164,0.001167599145409959
NCT01709162,Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma,0.0009841621553153275,0.0011902612144060521
NCT01782508,A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma,0.0009010648860252155,0.0008952205584213433
NCT02836548,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,0.0008450856582975969,0.001053508614387068
NCT02891616,18F-FLT PET Imaging in Patients With Advanced Melanoma,0.001178805086340504,0.0011766034521365084
NCT02879474,Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma,0.0010214795865605888,0.0008394829422267688
NCT02819843,"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",0.0008770521018483931,0.0009031860632738791
NCT02884362,Prospective Melanoma Database,0.0014522311135889445,0.0005295468764736092
NCT02883933,Clinical and Histological Features of Head and Neck Melanoma,0.0010396448989813008,0.0005818569447348643
NCT02828202,Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients,0.0013003731457421,0.0014558528661882783
NCT02828345,Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma,0.0012325229754006955,0.0012132347573430588
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,0.0007787673461928235,0.000967697131118825
NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",0.000828980306886796,0.0010330922751493356
NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,0.0010651802965102805,0.0008849786899646217
NCT02854657,Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners,0.0010709322137728865,0.0009422741352432829
NCT02897765,"A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",0.0010123002690480784,0.001169883312816766
NCT02818023,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,0.0010355720873369764,0.001314602434735959
NCT02838433,Study of Anti-telomerase T CD4 Immunity in Melanoma,0.0012588350082552923,0.001026178977156375
NCT02870244,Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes,0.0008851896468929465,0.0007618632251279708
NCT02862145,"Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions",0.0011368363171822655,0.0009740872846365816
NCT02862743,Molecular Characterization of Advanced Stage Melanoma by Blood Sampling,0.0008224306412926236,0.0008418726173081563
NCT02823405,X4P-001 and Pembrolizumab in Patients With Advanced Melanoma,0.0013661678605162058,0.0011010093890198578
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,0.001006834045798287,0.0010972785870232721
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,0.0015317801590371007,0.0012854555823210998
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,0.0008496982435005141,0.0007558573441571721
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,0.0014195077676450634,0.001442763579524666
NCT01528774,Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers,0.0007583176883183978,0.000884558303149558
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,0.0012189532430221283,0.0010739836525738514
NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,0.0011239744109751578,0.0013442315929755515
NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,0.001227135168795423,0.0010702924443278163
NCT01551693,STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma,0.0013003731457421,0.0010335388772838075
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,0.0012935446879646219,0.0010197608299589561
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",0.0009164110392339732,0.0009926437533221127
NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,0.0008660701912785408,0.0011687200706263826
NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,0.0010791548560369546,0.0010513744150087135
NCT01502293,Trial of pIL-12 Electroporation Malignant Melanoma,0.0010316871330176293,0.0010430636868186173
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,0.0010247759623302386,0.001056850898931906
NCT01558349,Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques,0.0014552199194163356,0.00109269351364156
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",0.0012423460512947604,0.0015169372489500462
NCT01531608,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma,0.0008547264361898529,0.0008658918448611481
NCT01531244,"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",0.0008188911018663049,0.0011582278145528951
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,0.0008449787254317999,0.0010647100062440497
NCT01500304,Minimally Invasive Groin Dissection for Melanoma,0.0008309743603282878,0.0008939734510298797
NCT01563614,"A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",0.0010101220674065495,0.0008284439594268354
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,0.0012425916050078575,0.001094383110525506
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery,0.0010897297644078513,0.0013945214185159256
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,0.000921236295055039,0.0009475665414327288
NCT01556503,Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis,0.0008472552387709736,0.0008742055221360096
NCT01503827,Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma,0.0007722596828107569,0.0007243735581892916
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,0.0012182573500519192,0.0007954970069436475
NCT01543113,"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project",0.0007828541456549636,0.0010833736038747337
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,0.0011282656892285072,0.0013611536879215107
NCT02203864,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,0.0011820892331446255,0.001215433735900304
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,0.0009049158457257224,0.000971024740219309
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",0.0010620430693726733,0.0011588733651566323
NCT02251314,Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma,0.0010701784280968412,0.0008442768561219183
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,0.00121817987272121,0.0014433602227505787
NCT02225366,Intratumoral Injections of LL37 for Melanoma,0.0014624347058910653,0.00109629280507197
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,0.0011042366944932248,0.0011469986262174084
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,0.0012181361494835441,0.0009978205169615367
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,0.0008722350654035257,0.0009854977113247002
NCT02211131,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,0.0009047412663505606,0.0010553382419015728
NCT02297529,Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma,0.0009825849880044511,0.0011513520882154233
NCT02236546,FDG-PET in Advanced Melanoma,0.0011917805640432406,0.0010678208059466377
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,0.0013597829795714872,0.0012989975546724044
NCT02263508,Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034),0.0008740260631317898,0.000814668475805442
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,0.001582985167305301,0.0011405666500556436
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,0.0008735328687342988,0.0011182828767160224
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,0.0011134131826641116,0.0012544713400205344
NCT02231775,Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo),0.001053612090456309,0.0011043512595876462
NCT00590824,Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma,0.0010710554876243793,0.0008261157641133159
NCT00591500,A Model for Genetic Susceptibility: Melanoma,0.0008332769006535662,0.0007287508061304227
NCT00591370,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,0.0012389142187810421,0.0010832387487045836
NCT00518206,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,0.0013052336404567988,0.0011726195028696988
NCT00518895,Trial of Dacarbazine With or Without Genasense in Advanced Melanoma,0.0009739341978929824,0.000914028344291144
NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,0.0009060314003199688,0.0009262044759351079
NCT00580060,"Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",0.0009914458708022698,0.0011380882266734318
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,0.0009684941735810251,0.0011313606086117923
NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,0.0012667392281050622,0.0009609881355247341
NCT00510302,Melanoma Risk-Reduction Among Patients and Family Members,0.0012176508296397055,0.0007065839301552244
NCT00584493,Treatment Use Study for Advanced Melanoma.,0.0011991384231963224,0.0014687207485409796
NCT00581698,Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue,0.000698296076541701,0.0008415868080488488
NCT00526032,Melanoma Detection by Oblique-Incidence Optical Spectroscopy,0.0010297781255303414,0.0006017615854340709
NCT00565968,Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg,0.0010300590618631598,0.0010169494471604528
NCT00596362,Treatment With Intravitreal Avastin for Large Uveal Melanomas,0.001110770200822089,0.0011063592978206964
NCT00533702,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,0.0010764296826774715,0.0010677071288630988
NCT00553618,"Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients",0.00101623372026349,0.0011323522024269124
NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,0.0010717015808356049,0.0011372427469171916
NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,0.0011731178593450832,0.0010382309739482868
NCT00525031,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,0.0010198701958237634,0.0013846659552690522
NCT00522834,Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma,0.0008490746980170206,0.000766134176335715
NCT00521001,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,0.0011168829807599156,0.0011042047178076034
NCT00585000,"A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",0.0012231124780737583,0.0013014499705346256
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,0.0010938964097283981,0.0012174847261218625
NCT00588198,"Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma",0.0009696405221451231,0.001239676572002097
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,0.0010662349699680608,0.001198900273398304
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,0.0012247509136243525,0.0013006230237769473
NCT00506311,Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients,0.0012265434595382897,0.0006935026561645017
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,0.001031594541000431,0.001004737928874279
NCT00568451,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,0.0011094811452715687,0.0010982995641273085
NCT00568048,Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011221880537303024,0.0010865275837034377
NCT00507325,Sample Collection From Melanoma Patients,0.0015308122161331425,0.0011994721070564631
NCT00536029,MicroRNA Expression and Function in Cutaneous Malignant Melanoma,0.0010278873041706597,0.0006722914617417593
NCT00512798,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,0.0011282157339374543,0.0010523085910193904
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,0.0014536899957354095,0.0009104888251952808
NCT00527761,Taxotere/Temodar/Cisplatin Study in Melanoma Patients,0.00112998993194613,0.0011058309292124526
NCT00527657,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010846241420573084,0.001053640591776239
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,0.001213357610476772,0.0008913844810153621
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",0.0010367726901889444,0.00103420203217731
NCT02739386,Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases,0.001158901622104883,0.0009787171448164202
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,0.0011219684124790523,0.0011064186484515876
NCT02791594,Imaging FDG Flare in Melanoma,0.0010352468530681516,0.00100449890808252
NCT02723721,Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face,0.0008343351924595151,0.0008379861597383659
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",0.0009289606343615413,0.0010489512151773193
NCT02717364,"Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma",0.0011046285820345782,0.0009474508982417633
NCT02799901,Nivolumab Plus Radiotherapy in Advanced Melanoma,0.000995229602927698,0.0008251640940623195
NCT02794636,Interferon Toxicities in Melanoma Treatment,0.0009052308729352171,0.0010514800385664008
NCT02716948,SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,0.0009898000875343937,0.0012094508314847302
NCT02716077,Early FDG PET in Melanoma,0.0014522311135889445,0.0007953668950286723
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0011807182460012078,0.001334759393132498
NCT02744209,Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients,0.0011241949817064971,0.001260055932736498
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,0.0008959679653879557,0.001165625988846612
NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,0.001072123190239636,0.0009717762556312416
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",0.0009114154935300846,0.0013451010687254756
NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,0.0009068315585854383,0.0009059044876125812
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,0.0012621598600321064,0.0011973146318212024
NCT02759536,In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma,0.0011126847298685426,0.0009124443082584117
NCT02700763,[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis,0.0010474973558197013,0.0009705954529829198
NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,0.0010121018247224239,0.0012007578445282921
NCT03028948,Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma,0.000985408538202718,0.0009525917334337523
NCT03084640,Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,0.000982946553859707,0.0009131400510266371
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,0.0008711588163412457,0.0009439747484943701
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,0.0007357684749382992,0.0007976437946856174
NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,0.0009728587505088997,0.0014064151927524239
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,0.0011302961618060066,0.0012585604147461352
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,0.001012370385289387,0.0010086580393610343
NCT03007823,High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma,0.0007836636848941261,0.0011981450294247776
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,0.0011898160692014339,0.0010471225034517982
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",0.0010495921446973487,0.0011010777280987241
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011063445366210217,0.0013131991187114204
NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,0.000999931267700497,0.0010432463286539253
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",0.0012197776270531475,0.0010139976447205582
NCT03086174,Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma,0.001029671164176816,0.001212773061568392
NCT03012009,Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial,0.0007269553553377871,0.00069042536451716
NCT03073031,The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy,0.0015528121761992542,0.0009359818397376326
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",0.0008369458305961339,0.0004988142247863265
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),0.001096111707098972,0.0011673147408294325
NCT03024866,Electronic Brachytherapy (eBx)-Mohs Matched Pair - Cohort Study A Multi-Center Retrospective-Prospective Matched Pairs Cohort Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx Compared to Non-melanoma Skin Cancer Patients Treated With Mohs Surgery,0.0010758919481140886,0.0009341282935141239
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,0.0012122387338361028,0.0013845209580887318
NCT03033485,18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis,0.0007541669512697529,0.0010048107488537172
NCT00203008,A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma,0.0011313982133758398,0.001182943706530105
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,0.0007882447379141876,0.0008406487146842232
NCT00255762,"Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",0.0010980017348020332,0.001079374582307851
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,0.001029948881740371,0.0011638927632566492
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,0.001017793745634993,0.0009568942956092005
NCT00243061,AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma,0.0016994488243279654,0.0013489780332884267
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,0.0010350612239071603,0.0010547468502613022
NCT00204529,Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB,0.001259802018811691,0.0012076178585488922
NCT00204581,Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases,0.0007698327208569238,0.0009346327273636832
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma,0.0010316444827047598,0.0012949736760024056
NCT00278122,Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011829942785069694,0.0012900432912006728
NCT00264056,Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases,0.0010723298309271007,0.001173640150910986
NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,0.0010832683995190635,0.0010404680422988625
NCT00281541,A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma,0.0010865065620728977,0.0014500443906954165
NCT00288938,Natural History Study of Moles and Suspicious Melanoma,0.0008890196871627462,0.0009130213178081585
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma",0.0007953412790718392,0.0012562453498576695
NCT00246012,"A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma",0.0009431659884051802,0.0011435065802985922
NCT00273910,Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma,0.000782387433509551,0.0014101177407241088
NCT00217542,Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery,0.001158658304127761,0.0011555262565254615
NCT00232726,Clinical Study of Previously Untreated Patients With Malignant Melanoma,0.001227072394705924,0.0011686324528009941
NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,0.0007798800577428812,0.0009636974261623331
NCT00289640,Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012901863608348776,0.0014775327356041875
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,0.0011717132671789762,0.0013510037358369566
NCT00289627,A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012253778670913425,0.00122001896809057
NCT00226473,Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma,0.0007489247081500081,0.001017180073124972
NCT00258687,"Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma",0.0008039872802183281,0.0010272262740587015
NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",0.0011772413558044897,0.0012467776249830273
NCT00272415,"A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",0.001119236934230311,0.0010255220989503116
NCT00287196,Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes,0.0007508675111062741,0.000667345870556961
NCT02366195,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,0.0007101118000542106,0.0009909490007054662
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,0.0008620373945715861,0.0008763113959174558
NCT02352623,Quality of Life and Surgical Late Effects of Melanoma Treatment,0.0009534643122520026,0.001107767687325712
NCT02335476,Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography,0.0008369414490822061,0.0006686344460746983
NCT02332668,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",0.0009259831514608717,0.0009942777686516699
NCT02310451,Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes,0.0008927065202353674,0.0011025228195947103
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,0.0014522311135889445,0.0009658591131323042
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,0.0009331345063181238,0.0011539328964982592
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),0.0009197285892066622,0.0008951168270423606
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,0.0012284752586142434,0.001165226764919335
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.0008347189603251203,0.0008386362637878062
NCT02375984,A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas,0.0008800827329054237,0.0010127599393153126
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),0.0009625051996691784,0.001033200837669934
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,0.0011326589875549666,0.0012371219407551499
NCT02385214,MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma,0.0010267191452551679,0.0006906542772640036
NCT02385253,Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance,0.0006982406507059282,0.0004777268132550339
NCT02374242,Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases,0.0012429921543129256,0.0012719098689885947
NCT02320058,A Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab by Itself,0.0011640064009118796,0.001117823481049473
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,0.0010174215645284786,0.0011705733139970194
NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,0.0008654401541718208,0.0007115983127940944
NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,0.0011027590781562957,0.0013123609238668782
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",0.001005754309481273,0.001160087895100384
NCT02302339,A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma,0.0012083434568319776,0.0012643529220954326
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC,0.0008711588163412457,0.0009335857725145555
NCT02331134,Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,0.000698961802607918,0.0008373349837084599
NCT02355574,5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results,0.0008025185671721798,0.0006539321881850459
NCT02355587,Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes,0.001131557191845481,0.0008524151786662555
NCT02307149,Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,0.001371184690862013,0.0014950216870879347
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,0.0027833208302349825,0.000921968141429719
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.000840632560089246,0.0007993061725766494
NCT02393001,Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques,0.0007023384570961441,0.0008036588662162776
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011318527963315543,0.0012626348875397762
NCT02339987,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,0.0008684728746674585,0.001246405836387205
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,0.0010940373842709245,0.0012146295280145963
NCT01308762,"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients",0.0011187050228899653,0.0013713805978591387
NCT01388569,Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim,0.0011042053548703699,0.0011893564081385775
NCT01336270,"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients",0.0010929606038531181,0.0010728594323347242
NCT01341158,NAM-Trial: Multiferon in Malignant Melanoma,0.0014522311135889445,0.0008331295852528547
NCT01328535,Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.001162835395011628,0.0013092062842773669
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,0.0011120032895427098,0.0012876168075217217
NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,0.0012297000838924067,0.0012253436332502392
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,0.0011676672826719764,0.0014088105717813622
NCT01311466,Liver Transplantation and Uveal Malignant Melanoma,0.0014522311135889445,0.0010331219661156097
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,0.0008819924399383747,0.0010416321813781527
NCT01356771,Melanoma Risk Assessment & Tailored Intervention,0.001024751983571967,0.0006695662026834433
NCT01302496,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011722613442916334,0.0010411977955211832
NCT01355120,THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease,0.001343444215210138,0.0011079242056931454
NCT01355562,Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer,0.0007476862017980432,0.0009628175380187646
NCT01359956,Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma,0.0008585227435481909,0.001032321722772432
NCT01397708,Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma,0.0009271769923559469,0.0010372807816502743
NCT01338389,Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy,0.0010005341282577327,0.0010381225816466437
NCT01316692,Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma,0.001194236740637556,0.0011479533791240153
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,0.0012578373346328322,0.0012941359136256797
NCT01363206,Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma,0.0008029621004718338,0.0009445258019525236
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",0.0010361252589705461,0.001363397931625539
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,0.0011809385048880926,0.0011745930623707805
NCT00813449,Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma,0.0011929035033739544,0.001036586829265034
NCT00871533,Pilot Study of IFN α2b for Melanoma Patients,0.0017619767387954636,0.001088425184498448
NCT00811759,Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma,0.001185937501930199,0.0011614641345630333
NCT00816374,Tailored Intervention for Melanoma Patient's Families,0.001529831914617664,0.0008296709188016223
NCT00831545,"Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",0.0008556529072153261,0.0009813071661320368
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,0.001259335126920568,0.001285029457591291
NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011774905708001786,0.0013131099827175265
NCT00862914,"Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi",0.000694992882619869,0.0006362186221670711
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.0010783214938154466,0.0010484750761279576
NCT00835419,Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression,0.0008995599508516644,0.0014004274491928302
NCT00835133,"Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma",0.0009620894613589653,0.0009519152282519784
NCT00861406,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,0.000837557646065976,0.0008794946102210496
NCT00849407,Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma,0.0007390301491022713,0.0007205661122211697
NCT00889980,Melanoma Molecular Profiling Analysis,0.0014567396398211376,0.0007618900069575287
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,0.0010748719815776152,0.001329269337284337
NCT00847522,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma,0.0010171315069618908,0.0010174566401639903
NCT00897520,Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy,0.0010903287683211892,0.0011737503026344495
NCT00897481,Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy,0.0011023773366772218,0.0011143287061565574
NCT00897546,Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma,0.0010831959755073564,0.0011486091764844213
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,0.0010666288199775286,0.0010838851708682077
NCT00809588,"Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)",0.0007024671308382318,0.0009150010838917436
NCT00841204,Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma,0.0010247801839988605,0.0008219564411718875
NCT00839410,Multicentric Cohort of Melanoma Patients in Ile de France Area,0.0015288445053938254,0.0009043104674034436
NCT00803374,Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma,0.001321111841895368,0.0016726721907898768
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,0.001121618643144235,0.0011771720721827424
NCT00846833,Haploidentical NK Cell Infusion in Malignant Melanoma,0.0008578759366483004,0.0009534911369963419
NCT01644591,Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases,0.0010050549885271655,0.0010538512670392756
NCT01673854,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,0.0010666316708681466,0.0015022157553183314
NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,0.0012623597319276244,0.0009691543503821979
NCT01676649,Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma,0.0011850284046913098,0.0010801672149961603
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,0.0009736905203361075,0.0010192418552225492
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,0.000997612584060581,0.0012506497476345115
NCT01636882,Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks,0.0015738396294533018,0.0012990707525955226
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),0.0012743281486595347,0.0011481565774273342
NCT01666418,Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel,0.0011682235006091,0.0013249368652991928
NCT01610531,COPARIME: Pilot Study of a Target Detection of Malignant Melanoma,0.001262869028157577,0.0008464116801877511
NCT01622933,Multiple Antigen-Engineered DC Vaccine for Melanoma,0.001489026276079812,0.0006639989195517215
NCT01681212,Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma,0.001283225841557483,0.0013504335124470495
NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",0.0010934218517656216,0.0011682265240630998
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,0.0010746046661583675,0.0014697009180354211
NCT01682083,A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,0.0009420008721106398,0.0010311504648080547
NCT01672450,A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma,0.001182584011620382,0.0010273802073205288
NCT01677975,"The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma",0.0009601683501506745,0.0011000595601144436
NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,0.0014522311135889445,0.0012156468314633484
NCT01662713,Optical Frequency Domain Imaging for Non-melanoma Skin Cancers,0.000845115193037403,0.0007998235571651475
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,0.0009064387012618355,0.0011200227998765268
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,0.0012422695221383881,0.0011688384721404222
NCT01667419,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,0.0011582421762203275,0.0008927013994149343
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,0.0010240283098313747,0.0011128111185177414
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",0.000987404056852181,0.0010271290957237812
NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,0.0013383477890786264,0.0011584397648254118
NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,0.0009034108860432988,0.0009399647421326272
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,0.00128187007086484,0.0011439298150065652
NCT01082198,Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes,0.0010940679679172249,0.0011103723903824667
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,0.0009656767071881529,0.0010219370781536117
NCT01039844,Study of Weekly LOC-paclitaxel Injection for Melanoma,0.001016113653495545,0.0010552663241093605
NCT01003626,Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients,0.0012126350894210668,0.0012425919170775742
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",0.0010263669239961764,0.001039045604975245
NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,0.0013292248584730398,0.0012355853337216599
NCT01067066,A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma,0.00107214254472925,0.0010593748003187844
NCT01085396,Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin,0.0006815009426177447,0.0007088420240514392
NCT01034696,Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting,0.000983590399988237,0.001067833293541679
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,0.0009839833104955656,0.0014286725575315341
NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,0.0007482414122592067,0.001110504489842071
NCT01021059,A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer,0.0008758284068096824,0.0014699031095385148
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0010762166136894737,0.0011255540644717651
NCT01002560,The Identification of Novel Prognostic Markers in Melanoma,0.0008477247214037629,0.0010181083636385082
NCT01077050,SciBase International Melanoma Pivotal Study,0.0017998036131506737,0.0007865499234137027
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.0011798103923352113,0.0011302959941776843
NCT01092585,Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH,0.001095261102968238,0.0010788962326165855
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",0.001004720194835852,0.0011941009092441537
NCT01011530,Dose Escalation Study of MLN4924 in Adults With Melanoma,0.0017998036131506737,0.0011654642843857753
NCT01009775,A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma,0.001046934538038201,0.0012077737895926947
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,0.0014148072195369656,0.0011136386644031767
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011810600459942117,0.0012537673859130038
NCT02425475,FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA),0.001029769831387711,0.000499011526503379
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,0.0009806761800433908,0.001031269196664959
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,0.000978539248655795,0.001026041247858893
NCT02442466,Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma,0.0008925922744792578,0.0008182710316312395
NCT02457065,Skin Care Behaviors Among Melanoma Survivors and Their Families,0.0010247924896913212,0.0007481599360259315
NCT02410733,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,0.001070398400121525,0.0013637870783260138
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,0.0008467473532359362,0.0010847992362251239
NCT02437279,Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients,0.001173487156454165,0.0013190498654578275
NCT02437305,Melanoma Perception and Health Literacy in People of Color,0.0008301912941549832,0.0006779965558581492
NCT02437136,Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,0.0009112301948910628,0.0009604748134040712
NCT02492815,"PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma",0.001132414699327936,0.0012706820972575277
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,0.0009704034310577377,0.0012000486159773139
NCT02452294,Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER),0.001076545450593229,0.0010409367803706692
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,0.0012508805837599835,0.0013990325642373558
NCT02470273,Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID),0.0010024874783787403,0.0007822995537834609
NCT02402699,Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan,0.0010923011515396677,0.0007772111002625034
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,0.0011931770447884196,0.0009094467284145868
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,0.0009576154785447501,0.0009827056916045017
NCT02434107,"Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)",0.0009691000059730522,0.0008337076812615826
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,0.0012394575072886803,0.0012132480068988824
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma,0.0009148568830640534,0.001337271950589679
NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,0.0009754391574173649,0.0010324438915620133
NCT02451488,Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma,0.0007392271282010531,0.0007083854017152629
NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,0.0008046348939217537,0.0009434211836166688
NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,0.0011092813142600723,0.001059424792695697
NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,0.0006961943585637265,0.0009090446364372566
NCT00104845,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012222844477483813,0.001277871937241595
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0013003731457421,0.0012636317758253238
NCT00104988,S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011188832804857928,0.0011362986777834019
NCT00104897,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma,0.0012652560286389527,0.0011392401807827884
NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,0.0011432925338922249,0.0012049887057765483
NCT00184067,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,0.0010149562047352453,0.001074646486998629
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,0.0011396610569448262,0.0010482236871554426
NCT00110019,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011559011313319826,0.001337895365499951
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010312579533837127,0.0010687113585553742
NCT00119249,Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011824391688154993,0.001181904049223263
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),0.0007597457216662753,0.0010388172394480133
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,0.001199447242472906,0.001353702064971421
NCT00109863,Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma,0.0013450059162964877,0.0013422639977215807
NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,0.0009768441595861001,0.0008919301573977786
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,0.0012280536676170372,0.0012459229316163225
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,0.0011886812325437406,0.001435884559041391
NCT00128583,Vaccine Therapy in Treating Patients With Malignant Melanoma,0.001583655028336547,0.0012707364678880913
NCT00199901,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma",0.0011513430610715148,0.0012443288174135876
NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",0.0012300387671010952,0.0009589679711934563
NCT00118313,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011736351841536636,0.001293129237805142
NCT00118274,"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011746021842168127,0.0013297558875794905
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0008504157985825767,0.0010550099531710833
NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,0.0013477937828023153,0.0010515795100198917
NCT00112216,Immunotherapy of Melanoma Patients,0.0015528121761992542,0.001104638727642519
NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,0.0011796437753920357,0.0013787287936227561
NCT00153569,Multiepitope Peptide Vaccination in Melanoma,0.001061247814026683,0.0008405633159355726
NCT00116363,Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma,0.001214400369975917,0.0015950639872474015
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,0.0012072216534205747,0.0012429606587206475
NCT00108875,"Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer",0.0010577556321748212,0.0012113435166948045
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,0.0010898480354830419,0.0010452331609583105
NCT00126685,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00138618083256665,0.0012009808827420324
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,0.0011370870139987372,0.0011275453230714465
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",0.0011553491319569414,0.0011013699505303487
NCT02180061,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),0.0011595329144775946,0.001318454076493008
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),0.0009714961417923518,0.000980091139544674
NCT02177110,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma,0.0008566400428701748,0.001004845508071598
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon,0.0010199039219579873,0.0011063577212432976
NCT02166255,"APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",0.001053671563632199,0.0011905250498583611
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",0.0009991719257003017,0.0010719908404750347
NCT02147951,"Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",0.0008785716464628464,0.0013503374976119315
NCT02193581,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0007015991603406935,0.0006983410236539
NCT02106598,"Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Gynecologic Malignancies",0.0006845800402918532,0.000955305600167727
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,0.0011245679664330045,0.0012588209024527884
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,0.0010401157886237326,0.0013253477942604022
NCT02190838,Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma,0.0007203981690843506,0.000845142476358597
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,0.0013095075581013235,0.0012479151358047356
NCT02158520,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011246087151639459,0.0013452069098726113
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",0.0008853002679942141,0.0010369019119268956
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,0.0011120163422255647,0.0012692110314054409
NCT02155322,A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400),0.0010821613375240505,0.0017629896068376534
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,0.0010342715337422804,0.001151368247705223
NCT02115139,GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases,0.0011544148678283074,0.0011790199323782572
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma,0.0010553583283082737,0.001130997724262111
NCT02142335,Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma,0.0011203643622434108,0.0012969613899755964
NCT02142244,Fluorescence Surgery for Sentinel Node Identification in Melanoma,0.0008920590937154713,0.0007374055058980726
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,0.0009982745106769176,0.0011767429071018738
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,0.0011588642411910364,0.0010802129430413448
NCT01174238,A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852),0.0008390420971417977,0.0009496658496795711
NCT01120275,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,0.001344372631835398,0.0011628672600681527
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,0.0008407722755467409,0.0006030032841929144
NCT01127594,Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion,0.0009895818070270563,0.001233652916444061
NCT01127451,Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma,0.001247148115364906,0.0013241574869045473
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",0.0011756012170043126,0.0013034176751396942
NCT01183936,Trial of Surgical Excision Margins in Thick Primary Melanoma,0.0010996823801933113,0.0009721447309746286
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,0.0012808227071906667,0.0011283219342072721
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,0.0010758856699184544,0.0008683907643073105
NCT01191294,Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma,0.000713662269984066,0.0005058662664059738
NCT01121718,NIR-Guided Sentinel Lymph Node Mapping in Melanoma,0.0010268818561364158,0.0007726993147743245
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,0.0008810404762047221,0.0011309690417263248
NCT01134614,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012040727055326916,0.0011512560810953627
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",0.0014003733467829113,0.0013125081862807937
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,0.000995335941625944,0.0010015138255646324
NCT01118832,Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi,0.0007189366151202558,0.0005856071021190359
NCT01168050,Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.,0.0008704679271380367,0.0008898988677183232
NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,0.0010472900487992313,0.0010315458309390203
NCT01136967,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",0.0010092791438580874,0.0011291427263729256
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),0.0008392867121977626,0.0009558724296541696
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,0.0027833208302349825,0.0013013198282516407
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,0.0008940168682121403,0.0009123352835297736
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,0.001371184690862013,0.0009823997837005273
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,0.0013355356703107961,0.0012013067732529607
NCT02009384,Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox,0.0008766861470502911,0.0009714027366849528
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,0.001259068782420787,0.001229528722065424
NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,0.0012563177765363834,0.001326185231421339
NCT02094391,"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",0.0011271059411123528,0.0009275520315500983
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,0.0012662823151133647,0.0011597419077100711
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,0.0008712801745026053,0.0011384250108521816
NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,0.0008621999987938806,0.0009843257393865907
NCT02056522,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0007015991603406935,0.0006983410236539
NCT02074605,Cognitive Effects of Interferon in Patients With Melanoma,0.0015417078476543133,0.0009724456678578898
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,0.001235502953927822,0.0013415861380155888
NCT02029729,RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER,0.0008689165327244059,0.0010266690674572256
NCT02058953,"CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases",0.0010378939260679452,0.0009749209845225783
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,0.0012420095166100964,0.0010552557833184463
NCT02088762,Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm),0.0012231434662350292,0.0007322677565306412
NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,0.0009160701020254845,0.0010572820874511673
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,0.0010513439115198825,0.001160510526399922
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,0.0008311661913519791,0.0009810389302001572
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers,0.0010918679836844228,0.0012535705400680366
NCT00938223,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",0.0010688319900874212,0.0010498320117888653
NCT00928902,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",0.0009946226261072057,0.0010561968803321665
NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",0.00107932940254925,0.001104777037982018
NCT00942162,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,0.0012537512143958355,0.0012318357914278342
NCT00936221,Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients,0.0010138468842600563,0.0009731724461581941
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,0.0012491924192220805,0.001331327805392917
NCT00966173,International Melanoma Algorithm Training Study - IMATS,0.0010142257246935275,0.0007578002497507051
NCT00920907,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,0.0008426189283718968,0.0010650779782423797
NCT00972933,Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma,0.0008150334973626008,0.0010539395882446026
NCT00901966,Sun Exposure and Melanoma in Agricultural Workers,0.001453707007631626,0.0006940891079660424
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,0.0008171535743480091,0.0011859912488124172
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,0.0012183839367544155,0.0011230819208183432
NCT00923169,Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma),0.001223523953875006,0.001374673880644461
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.0011392358093641522,0.0013288060725944015
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,0.000842990208377658,0.0007611175137805494
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,0.0010927662950439788,0.0011032000952296652
NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,0.0010139694991593274,0.0011760930658622586
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12",0.0011673051795126317,0.0009407548757251422
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",0.0010061555856384435,0.0010095269219663953
NCT00912730,A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma,0.0008948063045953397,0.0009029232845657746
NCT00912418,"Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",0.0011516674894193686,0.001022730676963924
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,0.000981547851636406,0.000985579011387221
NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,0.001155411442620187,0.0009473521276771293
NCT00961376,Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC),0.0010168043638731216,0.0012236018798323053
NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,0.0009906885652794853,0.0008566418125471576
NCT00962845,Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011780081382515002,0.0010737108978472341
NCT00991250,SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma,0.0010199039219579873,0.0015445494538425815
NCT00991991,"Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",0.0012026280313731125,0.0012623308781812414
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",0.001031382237666928,0.0011738153559910848
NCT00937625,T-cell Based Immunotherapy for of Melanoma,0.0014874552226949106,0.0012024680431745283
NCT00937781,Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690,0.0011648966164814645,0.0012297489540201286
NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,0.0013450893678564001,0.0012702030206113459
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,0.0010153238598508765,0.0011231076831236405
NCT00028431,Novel Adjuvants for Peptide-Based Melanoma Vaccines,0.001065540109557811,0.0009327586392226055
NCT00017121,Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.001034300579516408,0.0012263480176698592
NCT00006035,Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011639754783014861,0.001195323311577224
NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",0.0010266293842723618,0.0012109547843777357
NCT00006243,Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma,0.0012109468255487484,0.0013183474572490055
NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,0.0012307293072535085,0.0010139261912559296
NCT00006022,Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer,0.0010794925221233975,0.0012606183307727892
NCT00006113,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011995518932397013,0.0012722072304416749
NCT00006233,"Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",0.0010416258639158824,0.0012381829836191748
NCT00006249,Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma,0.00120512591509749,0.00111519648633059
NCT00084214,STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma,0.0010483864430353496,0.0014206006835665989
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,0.0011637339789621185,0.0012197100453466701
NCT00042783,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00138618083256665,0.001505523378834981
NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,0.001191333285350677,0.001171286282199525
NCT00087386,Tanespimycin in Treating Patients With Stage III-IV Melanoma,0.001329229528258451,0.0010987707321655177
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,0.0013952070590725135,0.0012929227663803873
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,0.0011397572191607392,0.0011162930115325665
NCT00083239,Study of Talabostat in Advanced Melanoma,0.0014199122717120903,0.0017023319033242748
NCT00083252,Study of Talabostat and Cisplatin in Advanced Melanoma,0.0011368407012375581,0.00135097568835943
NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00138618083256665,0.0014031383201014334
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,0.0014057733692349325,0.0015880764290658342
NCT00060125,Tipifarnib in Treating Patients With Metastatic Malignant Melanoma,0.0012652698134019095,0.0012462385507013172
NCT00016263,Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma,0.0010988951660558628,0.001082832872864095
NCT00010309,"Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",0.0012028236020996592,0.0014204805905017974
NCT00085397,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.0012319853288720946
NCT00085189,Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma,0.0012917330959915686,0.0014289975639183124
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.001277871937241595
NCT00085579,Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.001142775936611035,0.001086394532716767
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,0.0010705816209682112,0.001255728769085088
NCT00014625,E7070 in Treating Patients With Stage IV Melanoma,0.001344372631835398,0.001428487000716797
NCT00014092,Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery,0.0011323630251462886,0.0014087777293529044
NCT00049530,PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma,0.001344372631835398,0.001243988974417283
NCT00025181,Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery,0.0011838350065302842,0.0014014602552737164
NCT00003091,High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma,0.0010232852321771767,0.0011507502617341952
NCT00003266,Methylphenidate in Treating Patients With Melanoma,0.0015288445053938254,0.0009414026807584812
NCT00003646,Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012611032532961308,0.0015133245292960006
NCT00003509,Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,0.0012226108050175865,0.0010860958847071103
NCT00003641,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,0.0010952116278119745,0.0010575103282499238
NCT00003911,S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,0.0007297115077847719,0.000952268477063006
NCT00003346,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.001260507845115887,0.0013396604027431634
NCT00003308,"Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",0.0009951356259441007,0.001129014073298454
NCT00003647,Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011884072840455337,0.0012135736749517973
NCT00003556,Vaccine Therapy in Treating Patients With Melanoma,0.001583655028336547,0.0014255511259384508
NCT00003715,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,0.0011950563296693033,0.0011314287759622613
NCT00003789,Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg,0.0010585777503307834,0.0009598623357652549
NCT00003897,Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma,0.0011072281219753146,0.001360313501460083
NCT00003895,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,0.0012696839440621054,0.001225877153576119
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012060220323196343,0.0013572227932575922
NCT00003828,S9804: Vinorelbine in Treating Patients With Stage IV Melanoma,0.0013451396127688322,0.0013158212229225975
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00138618083256665,0.0013996303158081164
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,0.0012116048213557898,0.0013327710213595397
NCT00003339,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,0.0012014189457235833,0.0012647544480262718
NCT00062491,Study of Karenitecin (BNP1350) to Treat Malignant Melanoma,0.0012578623502876025,0.0019088273880830727
NCT00091689,Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions,0.0007902646285398896,0.0010893883925768874
NCT00057616,Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.,0.0009330828535578587,0.0010231743758586517
NCT00055562,Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma,0.000928738503982824,0.0010161944131675236
NCT00040352,"Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma",0.0008502661198699507,0.0009579693966441763
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,0.001321443740764608,0.0010798168299786832
NCT00077532,Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma,0.0010599712779885142,0.0011619687421268521
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.0014403512530081562
NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00138618083256665,0.0013854096105931195
NCT00039091,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",0.0009587483072029952,0.0008635825951654081
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,0.0009086884717471015,0.0010153765776101712
NCT00039234,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver,0.001085922366740001,0.0010609788792830502
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,0.0010325299361157807,0.0011834610168767238
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,0.0013703163231832895,0.0012392030879251124
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,0.00138618083256665,0.0011837151745974102
NCT00059800,Boron Neutron Capture Therapy in Treating Patients With Melanoma,0.0015317595507939297,0.001358256462360867
NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,0.0011858380427317453,0.0013987200702381484
NCT00072163,Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma,0.0010307391939682027,0.0010772445753853717
NCT00072124,Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma,0.0010982515976712284,0.0011321115781983968
NCT00072345,"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",0.001153651609196075,0.0013768368548949998
NCT00020358,Vaccine Therapy in Treating Patients With Melanoma,0.001583655028336547,0.001419286024727674
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,0.0011103550387517142,0.0010331213554686356
NCT00068172,Study of PI-88 in Patients With Advanced Melanoma,0.0015197705506361824,0.0020779330823279974
NCT00068666,Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System,0.0010876263290911467,0.001057794698673303
NCT00036764,BMS-247550 in Treating Patients With Stage IV Melanoma,0.001344372631835398,0.001428487000716797
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,0.0010701839520129547,0.0013817164565585417
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.0010477521463389849,0.0010987541593117077
NCT00002763,High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma,0.0011168175904853167,0.001051633955374345
NCT00002781,Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma,0.0013311688342015873,0.0013248975954489254
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,0.0010910657858469559,0.0012842838371307386
NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,0.0010787858897112518,0.0009932196778914086
NCT00002535,Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma,0.0011694995965355565,0.001227794667381742
NCT00005057,Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma,0.0011690835340209254,0.001228174407551556
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,0.0012039345677916135,0.0013954422116264666
NCT00005815,Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma,0.0011830199565585515,0.00136645417068564
NCT00005633,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.001277871937241595
NCT00005610,Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0011309271729056552,0.0011498788990643464
NCT00005968,Irofulven in Treating Patients With Stage IV Melanoma,0.001344372631835398,0.001428487000716797
NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.0012797369460085738
NCT00005971,Flavopiridol in Treating Patients With Metastatic Malignant Melanoma,0.0012645392959938797,0.0013600901034287027
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,0.0011938398503960061,0.0013582118974743572
NCT00086866,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery,0.0012090002719189915,0.0012207227147147254
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",0.001691901740720678,0.0015506017342443285
NCT00004244,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma,0.0010411020826165277,0.0010199456295188706
NCT00004135,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer,0.001040481453852794,0.001216337187153818
NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,0.0012051370261374566,0.0014882454728851234
NCT00004250,Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery,0.0010049027887569818,0.0009479407864660702
NCT00004104,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,0.0011171770744780882,0.0011184787368559586
NCT00004184,Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012618020517633673,0.0012549298420868947
NCT00004153,Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma,0.0010099845370990007,0.0007992525585286653
NCT00004152,PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma,0.001135021104577562,0.001032452075661249
NCT00004025,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012060220323196343,0.001506838619791951
NCT00004196,Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis,0.001084034165862717,0.0012090346448924755
NCT00080353,Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma,0.0008939215190179195,0.0014693432699164294
NCT00024011,PS-341 in Treating Patients With Metastatic Malignant Melanoma,0.001265264195605254,0.0013604111244487549
NCT00001296,"A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma",0.0010433542046771477,0.0008337891286541932
NCT00001685,"Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",0.0009985501415237243,0.0011402847825731303
NCT00001439,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,0.0008938020595106772,0.0009792909373454815
NCT00001577,Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity,0.0008397113155927991,0.0007257677464132749
NCT00035165,EPO906 Therapy in Patients With Advanced Melanoma,0.0014057733692349325,0.0012950422781920724
NCT00007969,Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012599205866654299,0.0013570056009802136
NCT00026520,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,0.0011772377712958248,0.0013124313563876867
NCT00026221,Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011156424865887316,0.0009770257920282447
NCT00026143,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.001111804943547647,0.0012387945290558502
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.001467755393503086
NCT00098553,Everolimus in Treating Patients With Stage IV Melanoma,0.0013458383567055844,0.0011335916417033757
NCT00089193,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0011826841244989815,0.0011495281374182043
NCT00089219,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",0.0012307009074979142,0.0012730013929607364
NCT00089063,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,0.0011503157918447277,0.001102182523204032
NCT00089206,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0012090002719189915,0.001262371605372609
NCT00073892,PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma,0.0012850187686669688,0.0014163726613245424
NCT00032045,Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0012052171099599007,0.001261921029889313
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",0.001151725513012002,0.0012869608241558928
NCT00031733,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,0.0010190483675053589,0.0010959059634064014
NCT00095108,Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer,0.0009464053829567522,0.0009801752173205433
NCT00070642,CPG 7909 Injection in Melanoma,0.0014624347058910653,0.0012630672859929746
NCT00070343,Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301,0.0011137138367602313,0.0011556815724181324
NCT01456104,Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma,0.0010032906821178713,0.0011171066034688013
NCT01496807,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,0.0008710421303313351,0.001007943620490156
NCT01460875,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,0.0015386513138223575,0.0015105089137859196
NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,0.000902103396987633,0.0010618120565473728
NCT01409733,TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients,0.000989963680142994,0.0011073616028067996
NCT01489423,Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim,0.0011618343592504376,0.00120989366926166
NCT01489059,Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma,0.0011154112912743033,0.001054212011447623
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),0.0009930032983549737,0.0011258371549065112
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,0.0014522311135889445,0.0010973271196857417
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",0.0010650003898573972,0.0012188419499107308
NCT01444560,"miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi",0.0007483593644047913,0.0006582234892625876
NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,0.0008406952266738076,0.001076303368635874
NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,0.0011140165840128327,0.0011205928949020436
NCT01432860,A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination,0.0010005347144093845,0.0006427227585408674
NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",0.0011688033612322934,0.0010810688241470728
NCT01453361,Phase II FANG™ in Advanced Melanoma,0.001186805825819988,0.0009667815059468349
NCT01469455,DNA Repair Inhibitor & Irradiation on Melanoma,0.0008541968343500757,0.0011063429304532192
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,0.0010228293677028778,0.000905723164786018
NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,0.0011354944814626054,0.0012569206836392953
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,0.0013583651399899938,0.001128260229968651
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,0.0009395866854856356,0.0009871823651520057
NCT01455103,Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma,0.0011482399293479312,0.0014287973868615654
NCT01295931,Nuclear and Near-Infrared (NIR) Imaging in Melanoma,0.0014687276701933578,0.0006603400799368027
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",0.0009344125921848098,0.0011441568954393617
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,0.001413249665779005,0.0013124718532661732
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,0.0015309073310743495,0.0015046178156741547
NCT01213732,Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma,0.0009217485712456692,0.0008925190008228506
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,0.0011017722643313847,0.0010618317392033162
NCT01259934,Nordic Adjuvant IFN Melanoma Trial,0.0027833208302349825,0.0010694217457138193
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma",0.001094942632571896,0.001221817096087243
NCT01227551,A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma,0.0013467201105600496,0.001263404374150236
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,0.001098578061052361,0.0010374999673606708
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,0.0011471118630186504,0.0011270603488081632
NCT01216787,"RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",0.001172000192168879,0.0012937893549330292
NCT01256359,Docetaxel With or Without AZD6244 in Melanoma,0.0014567387613007097,0.0012433375804494645
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,0.0009018182164289309,0.0010009737457639548
NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,0.0010807957800234305,0.0013716921775195129
NCT01280565,A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit,0.0013383229123977657,0.0010536270160705567
NCT01281722,Role of SLURP-1 in Melanoma and Melanoma Stem Cells,0.0008554042926300906,0.0008208384764634467
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,0.0009868832620039143,0.0010531084569478531
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,0.0008910021038971722,0.001002444262348736
NCT01205815,Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment,0.0012918373269721136,0.0011025119735350608
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,0.0011339668115867409,0.0013387092113608544
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,0.0011292831598845284,0.0013184841343057438
NCT01209676,IMCgp100 in Advanced Unresectable Melanoma,0.001006138560936491,0.0007870146383167582
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,0.0007200216092321613,0.000864056742524026
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,0.001194350710584459,0.0011992879088740256
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,0.0012213927972218941,0.000985431721786592
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0010923249266781693,0.0012753349619529658
NCT02941744,A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases,0.0007439475981950872,0.0008375100271643755
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,0.0008450999296856849,0.0009519891465686878
NCT02990611,Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma,0.0011818754212904047,0.0011436019477808511
NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,0.000944884464013323,0.0008856027316804284
NCT02907827,Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.,0.0009969477931336323,0.0006782583380691926
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,0.0010711459112669936,0.0010517166891068365
NCT02975700,A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma,0.0012935446879646219,0.0013362626139582967
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,0.0008265207797968118,0.0012774909245861867
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,0.0009489610748605962,0.0011081009692858656
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,0.0010406618985856874,0.000995934154798467
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,0.001219514101879827,0.0013600949144818816
NCT02909348,Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab,0.0011381127901500612,0.0010387541679922428
NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,0.0009175801788133978,0.0010679790045411883
NCT02994498,DCB-BO1301 for Advanced Melanoma,0.0016960965671080192,0.0012940844850532253
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,0.0011072085482163238,0.0012592939461900906
NCT02905266,A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,0.0009003824526261488,0.001017000000742779
NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",0.0010446496135476126,0.0009033398559225231
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0013541648457889419,0.001353064331639981
NCT02962947,MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients,0.001224323401557529,0.0011627727744955463
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,0.0010128952748046176,0.0009569138628051346
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,0.0015574681944806996,0.0011232199867927967
NCT02915666,A Clinical Trial of Patients With Melanoma,0.001538672478061963,0.0011214678408807525
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,0.001020742970175898,0.0011149919942481368
NCT02910557,Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection,0.0012126350894210668,0.0011026483249987802
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",0.0009567599588418429,0.0009867917980417396
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,0.0009818012128998944,0.0009388434732560101
NCT02507947,SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access,0.0010972943530439343,0.0010098110145544458
NCT02507076,Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma,0.0010242536329243797,0.0011437833724232639
NCT02519322,Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,0.0011360727594455762,0.0011646768985341467
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Hodgkin Lymphoma or Other Solid Tumors",0.0008227289795578011,0.0007932794271775292
NCT02508909,Videoscopic Ilioinguinal Lymphadenectomy for Melanoma,0.0014537133868511858,0.0006731964840385664
NCT02545075,A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine,0.0008566781174954394,0.0010243475449475904
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),0.0011007606170177799,0.0010771469050810817
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,0.0008122838093740007,0.0011402698563320616
NCT02511119,Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma,0.000698867014749661,0.0007514344979992025
NCT02574377,myDC/pDC in Stage III Melanoma Patients,0.0016782953589298253,0.0012068406973235553
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,0.0010157286562208266,0.0012582278872278147
NCT02509598,"A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping",0.0010987824404109024,0.0009404323724701336
NCT02565992,Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma,0.0011595329144775946,0.0010162619792960018
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,0.0011495100624852837,0.001333262771047639
NCT02506153,"High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",0.001132497175563645,0.001124882400882526
NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",0.0011485148817959965,0.0011089067717498643
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,0.0010802470896180652,0.0010953521201841284
NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients,0.0015624202368178643,0.0019128967768364995
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",0.0008991126098268669,0.0008173975755900289
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,0.0008711634559354512,0.000822498228522512
NCT02587650,Trial of TKF Inhibition in Unresectable Stage III/IV BRAF/NRAS WT Melanoma,0.0009957886277251412,0.001084213767551386
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,0.0007269346208846587,0.0010440093405873782
NCT00626405,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,0.0011003742949115066,0.001129644466874981
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,0.0011312103371565567,0.0014012016224204185
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,0.001691901740720678,0.0012573443563967332
NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011774905708001786,0.0013131099827175265
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",0.0009708052153450588,0.0006731765982247147
NCT00667953,Study of Temzolomide and Gleevec in Advanced Melanoma,0.0011338914464860985,0.0011803511419417002
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,0.0008215088633220994,0.0014511517284333314
NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,0.0009174485008695037,0.0008419914682147396
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",0.0009569021169437049,0.000957597575957288
NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,0.0008807519573670853,0.0011876303809507142
NCT00610857,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,0.0011118717722929706,0.0009658775976945015
NCT00625768,Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma,0.0011646159330932682,0.0011789800045667292
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,0.000875389666620466,0.0010898489206322044
NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,0.0007627258818191223,0.001299570514636157
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,0.0008087833761775161,0.0010389382583985195
NCT00672321,"Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma",0.0009993036004362003,0.0007283038601576446
NCT00669019,Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011765905222126626,0.0012141412342054534
NCT00658892,Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.001347280991231039,0.0009192299884429186
NCT00658437,CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy,0.0010252435589122634,0.0012369671391008444
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,0.001092740372055216,0.001202737256906379
NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,0.000996404309468147,0.0011920485307098925
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",0.001458316453352403,0.0011494209346890145
NCT00675727,Safety Study of CADI-05 in Patients With Advanced Stage Melanoma,0.0013464387461256102,0.0012540922102585496
NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,0.001019013679267019,0.001070770341425671
NCT00601861,Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer,0.0007580571263505699,0.0007367242063523273
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,0.0010606441732002416,0.0010473028161943664
NCT00602576,Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma,0.0010817361810726211,0.0010610410581051437
NCT00615095,Differential Risks for Melanoma: p16 and DNA Repair,0.0014537478652261694,0.0007837300925386984
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,0.001453788698728308,0.0009490504040935212
NCT00698100,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",0.0011031028932977356,0.0010212864049155652
NCT00671554,Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma,0.0010306981914156986,0.0010927150275824161
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.0007062384180736546,0.0006307868654236086
NCT00398073,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012222844477483813,0.001201097698887003
NCT00349206,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.001067364395493345,0.0010607734177279185
NCT00306553,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001115971140806679,0.0012324897855700472
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,0.0010957705834549853,0.0011335712627554653
NCT00306514,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001115971140806679,0.001214281814404646
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,0.0010247719074490899,0.001050349507392483
NCT00383292,A Study of LY573636 in Treating Patients With Malignant Melanoma,0.0017619767387954636,0.0013224104462729433
NCT00383851,Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma,0.0009781039446178405,0.0011439347872703267
NCT00328861,Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer,0.0008605799601048347,0.0013948641078744756
NCT00346008,Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members,0.0015307974375375441,0.0008574066931282266
NCT00368615,Characterization of the Melanoma-Specific Immune Response,0.0008548562711546516,0.0010276055950121116
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,0.0008331668685666639,0.0005394837298504775
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,0.0014582447319264732,0.0008828174925449363
NCT00348088,Melanoma Biomarker Study,0.0012756941259414922,0.0009286742163641203
NCT00304200,Temodar and Sutent as Therapy for Melanoma,0.000896878880152877,0.0009832026526219151
NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.0011724399003300821,0.0010375026061284797
NCT00394134,Targeted Intervention for Melanoma Prevention,0.0010267925874286779,0.000705389206670553
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,0.0010773404516080526,0.0008984434719758195
NCT00356460,Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma,0.0012598718070534606,0.0009203081353586706
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,0.0013466533248100525,0.0012777140751869312
NCT00387751,Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011652884961134966,0.0010609917093802738
NCT00391300,Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions,0.0009642511828271715,0.0007495069148570574
NCT00341991,Molecular Epidemiology of Cutaneous Malignant Melanoma,0.001027255818614826,0.0007467577383797151
NCT00357461,Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma,0.0012554468522343173,0.0012237593804460861
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,0.0011794835262015268,0.0011552100994932871
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,0.0010394775019413965,0.001413790273072576
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012947743430697042,0.0012431585581229529
NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,0.0011692526291378908,0.0013297027890502484
NCT00327600,Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma,0.0009731756227416935,0.0010721921932557985
NCT00339222,Family Study of Melanoma in Italy,0.0014522311135889447,0.0007396953193499598
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,0.0008472240122091244,0.0009847291954732738
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,0.0010264911907230452,0.0010814830314561093
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,0.0010316871330176293,0.0010415670489230184
NCT00791271,Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion,0.0008422721785468182,0.0009063138664415148
NCT00723710,Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600),0.0011198336475045873,0.0010030505326123352
NCT00794235,Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,0.0008548910985187701,0.0009624689797277188
NCT00790010,Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma,0.0011586735529487589,0.001136288663130812
NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,0.0009317700108529453,0.0009764037866936958
NCT00749684,Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083),0.0009030376292445332,0.0008414869488908245
NCT00716495,"Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma",0.000996302928184462,0.0010309798401037153
NCT00726739,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.00120863605589304,0.001188186237487891
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,0.001398188071593196,0.0015953826200866621
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",0.0011125959391786258,0.00104636895514094
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,0.0010154108662624134,0.001120347956901829
NCT00796445,"A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",0.0011445241538921833,0.0011327213388998157
NCT00707161,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,0.000849937319673615,0.0011237353172065274
NCT00788775,"Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",0.000991795716688959,0.0009459913030979186
NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,0.0011020529228281033,0.0010616686744362026
NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients,0.0012456171927346079,0.0014235635273763408
NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,0.0011844935896324074,0.0011912693608645203
NCT00776945,Feasibility and Functionality of fPAM Imaging in Melanoma,0.0010362612577130854,0.000656341879509955
NCT00743496,"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",0.0007422405939290222,0.0009501256856111792
NCT00705640,Vaccine Therapy in Treating Patients With Advanced Melanoma,0.0013823193379105525,0.0012724128125235822
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.001127418779625677,0.0011911156182254918
NCT00445783,Study of Families With Melanoma,0.0017998036131506737,0.0011099670974922752
NCT00466687,Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma,0.0011754874839316049,0.0009845836064627826
NCT00477906,M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma,0.001052421798378968,0.0013604831725376285
NCT00450255,VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011765905222126626,0.001095848587920644
NCT00450593,Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma,0.0012167165172983446,0.0011093852756029982
NCT00457418,High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2),0.001144470134051893,0.0011502457935732044
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",0.0010521876160595562,0.0010500401631030718
NCT00412828,A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010443889731693334,0.0010010014062086473
NCT00409383,Abraxane and Temodar Plus Genasense in Advanced Melanoma,0.000845954376228566,0.0009971548898972478
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,0.0010093644296516665,0.001401069028973639
NCT00472459,PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer,0.0007416857779408609,0.0009541595356051551
NCT00463892,High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes,0.0007145677680597321,0.0009452799902093023
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,0.0012189124644096968,0.0009331588354064654
NCT00436605,Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma,0.0011774289621412607,0.001156219625048583
NCT00462280,Lovastatin in Treating Patients At High Risk of Melanoma,0.001221923116188702,0.0014070167808539296
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",0.0011785261586742324,0.001074960366085946
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,0.0010855704041621208,0.0011438431195306975
NCT00447356,High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma,0.0010903041322843092,0.0009566006359721904
NCT00406900,Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma,0.0007919448980662232,0.0009471288218114434
NCT00432107,A Study to Assess APO866 for the Treatment of Advanced Melanoma,0.0011991384231963224,0.0011145308278335826
NCT00432471,Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers,0.0010329446465988407,0.0008024031166067326
NCT00416988,Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants,0.0007451330629296414,0.0005749677760491766
NCT00404235,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011508996466391868,0.0011203333629092168
NCT00470015,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",0.0011472910394941126,0.0011712873638359143
NCT00470379,"Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",0.0011801742811302775,0.0011795532717257511
NCT00470470,Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011770091125152952,0.001214433937389696
NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",0.0010941396493279003,0.0011844832025605183
NCT00438009,A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients,0.0013959446839357005,0.0009880953075501891
NCT00471133,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,0.000838771484211768,0.0008615582101206781
NCT00471887,"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",0.0011958450969755238,0.001043731695482468
NCT00471471,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012090002719189915,0.0011539591840915662
NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",0.0008212163369417415,0.0009077880544556287
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",0.001030278423611967,0.0007877869182503891
NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,0.001104082990367721,0.0011160645373077139
NCT00482105,Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells,0.0006987736042370956,0.0006367879665570634
NCT00495066,Compassionate Use Trial for Unresectable Melanoma With Ipilimumab,0.0009451579797179982,0.0009960770670511758
NCT01886235,Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery,0.0010422323411568236,0.001222413982571419
NCT01840527,Utility of Novel BRAF Test for Melanoma,0.0014595644922018366,0.0009197207396307128
NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,0.0012598443481514293,0.0009707344667298386
NCT01888081,A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma,0.0008541314214048028,0.0010412142472635184
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,0.0010360791530396906,0.0010396231464109274
NCT01864538,A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma,0.0011482399293479312,0.0011830861448552273
NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",0.0009463719960098553,0.0009525867682040113
NCT01826864,Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma,0.0010238206802312352,0.0013150308719574973
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,0.001022853041071737,0.001159127838139694
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",0.0011585753375663835,0.0013639331258344528
NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,0.0011886456292871973,0.001592628941724706
NCT01867619,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010846241420573084,0.0011064718049781516
NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,0.0010888844701942959,0.0012056225604131262
NCT01878396,Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors,0.0011205784967748826,0.0013767400093546063
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,0.0009991719257003017,0.0013986415948402727
NCT01859845,Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma,0.0006810896448596274,0.0006912391462147271
NCT01866319,Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006),0.0009763088114247195,0.0009988271357551808
NCT01844505,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),0.0009693614152101141,0.0010957338326611262
NCT01898403,Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma,0.0010673672274846488,0.0010670749372566819
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,0.0013228109279180944,0.0010267949371546559
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,0.0010595668774906906,0.0012119038245649142
NCT01851408,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.001067364395493345,0.0010607734177279185
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001137010039258892,0.0011783748189663854
NCT01920516,Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment,0.0008052112662615041,0.0010745911751222307
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,0.0010739926144900313,0.0011478911035085573
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",0.0010651212016994911,0.001152195934965719
NCT01989572,Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma,0.0010930696525636803,0.00124987399361454
NCT01989559,Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery,0.0010047494096806432,0.0011493936709118856
NCT01996202,A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma,0.0009027217414367396,0.0009084357619065828
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,0.001371184690862013,0.0021292903527523966
NCT01959633,Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,0.0012155471356747735,0.0012836576552090438
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,0.001093529308926433,0.001071645951756795
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,0.0009307709455816145,0.0013391525977017433
NCT01944709,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma,0.0012803908541560293,0.0012384079240201568
NCT01986712,A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma,0.0011287043443220885,0.0011083925931467335
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",0.0010987149023587732,0.0012548254829882386
NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,0.0007616836486216583,0.001068407050664679
NCT01973608,MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma,0.001186805825819988,0.0007515586863442817
NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,0.0011886377964636867,0.0014345460995234217
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,0.0014893461112971062,0.001103546480640629
NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,0.0011874992020411278,0.0013559647874349424
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,0.001263789263137074,0.001018517888489191
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,0.0012206032301365173,0.0011472956314795032
NCT01904123,A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma,0.00123399657539904,0.0011085056817940744
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,0.0009269101781820944,0.0011805968461969611
NCT01988831,Efficacy of Propranolol Treatment to Prevent Melanoma Progression,0.0007940763323251361,0.0009449261967819991
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",0.0007379264182498627,0.0008570403447039501
NCT01984255,"A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",0.0010817893682540864,0.0009703744459286362
NCT02694965,Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma,0.000860628599703218,0.0009057386612469959
NCT02602756,Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas,0.0010116954476530873,0.0008407298881761645
NCT02605473,Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion,0.0008422721785468182,0.0009496550568011253
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,0.0009376788872021351,0.0009476612907074515
NCT02696356,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,0.0012736039511207864,0.0011848750365433742
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,0.0010110918570242985,0.0007806491436460825
NCT02671513,A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients,0.0013214364000055379,0.0017576831662966784
NCT02613325,fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth,0.0008349753663940868,0.0009201540926476328
NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,0.0011482383029618071,0.0009937823369123879
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,0.0007399436632394428,0.0009773132471941593
NCT02600169,Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab,0.001026679076584307,0.0011202764575336003
NCT02600143,Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.,0.001006794425482591,0.0008379012028843272
NCT02668887,Employment and Quality of Life in Patients With Malignant Melanoma,0.0015317749843300342,0.0010502246715220136
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,0.0009115105512369672,0.0008432478633622096
NCT02673970,Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma,0.0011088109533053396,0.0011633286581307545
NCT02662725,Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases,0.0011324005300725366,0.0009120436342617281
